現(xiàn)代脂質(zhì)三聯(lián)治療ppt課件-免費閱讀
【正文】 Opinion 2022。 MMV Medizin Verlag, 1993: 43 PROCAM Heart Study HDL as CHD risk factor showed 186 events, in men aged 40 60 years (n = 4407) CHD Incidence per 1, 000 in 6 years 0 20 40 60 80 100 120 140 160 ? 35 35 55 ? 55 HDLC (mg/dL) 110 30 21 ASSMANN G。 101: 477484 LDL/HDL Ratio as Therapeutic Success Placebo Statin 24 116 31 245 0 50 100 150 200 250 300 = 5 5 LDL / HDL Ratio Triglycerides 200 mg/dl Triglycerides = 200 mg/dl CAD cases per 1,000 subjects in 6 years ASSMANN G and SCHULTE H?，F(xiàn)代脂質(zhì)三聯(lián)治療 Introduction Part I Efficacy The Power to Reach Target Key Factor: + Differentiators: LDL Reduction TG HDL LDL/HDL Ratio The Lipid Triad The LDL/HDL Ratio Our Strength, Our Story!! Clear positioning for Lipobay A new perception of efficacy Differentiation to Atorvastatin Fit with our product profile LDL HDL Additional risk factor, especially in diabetics The Lipid Triad Overview TG The Lipid Triad The Ratio The Lipid Triad and Strategic Rationale Part II ? No scientific evidence ? Evidence contradicting this statement ? A marketing hypothesis to build their LDL story ? Creating the perception of the statin with the strongest efficacy It’s logical It’s measurable It’s practicable The Lipid Triad The GP’s Perspective Supporting Data from Landmark Studies Part III 12 10 8 6 4 2 0 % Mortality Placebo Q1 Q2 Q3 Q4 (low HDLincrease) (high HDLincrease) 4S Study CAD Mortality per Quartiles of Increases in HDLCholesterol KJEKSHUS J amp。 Am J Cardiol 1992。 Lipid Metabolism Disorders and CHD。 16 (2):8087 LDLC (mean % change from baseline after 24 weeks) 10 40 30 20 10 0 50 % Men ( n = 200) Women ( n = 102) % LDL Cholesterol Reduction From Baseline OSE et al. Curr Med Res amp。nster, Germany The Lipid Triad Expert Comments The Impact of Guidelines Part V The Lipid
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號-1